Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Flow Pharma Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The case is assigned to 1 distinct examiner and a single distinct art unit, showing a concentrated review process. This arrangement suggests that the company's current filing falls within a specific technical area handled by a single examination team.
BANERJEE, KOYELI is the busiest examiner, managing 1 pending office action. This represents the total pending workload for the portfolio, meaning that the company's current prosecution success is entirely dependent on this one interaction. For the practitioner, this requires a focused approach to addressing the examiner's specific concerns. The existence of only a single pending office action indicates that the company is currently maintaining a very lean prosecution pipeline within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550416 | MICROSPHERE FORMULATIONS COMPRISING MULTIPLE NON-IDENTICAL PEPTIDES AND METHODS FOR MAKING THE SAME | BANERJEE, KOYELI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550416 | MICROSPHERE FORMULATIONS COMPRISING MULTIPLE NON-IDENTICAL PEPTIDES AND METHODS FOR MAKING THE SAME | BANERJEE, KOYELI | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFlow Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Koyeli Banerjee has the most, with 1 of Flow Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
